Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 9,516 shares, an increase of ? from the July 15th total of 0 shares. Based on an average daily volume of 95,837,372 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Trading Up 100.0%
OTCMKTS:RGBP opened at $0.00 on Tuesday. Regen BioPharma has a 12 month low of $0.00 and a 12 month high of $0.04.
About Regen BioPharma
Regen BioPharma, Inc is a development?stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell?derived receptors and peptides, the development of immuno?oncology assets, and the filing of investigational new drug (IND) applications to support first?in?human studies.
Featured Stories
- Five stocks we like better than Regen BioPharma
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
